Celldex Therapeutics, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $28.04
- 52-Week Range
- $22.33 – $45.14
- Market Cap
- $2.16B
- P/E (TTM)
- —
- EPS (TTM)
- -4.29
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.33
- PEG Ratio
- —
- Return on Equity
- -49.54%
- Return on Assets
- -30.52%
- Gross Margin
- 0.00%
- Operating Margin
- -211684.81%
- Profit Margin
- 0.00%
- Current Ratio
- 10.97
- Debt/Equity
- 0.02
- Total Debt
- $9.87M
- Free Cash Flow
- $-154.39M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.52B
Market Snapshot
About
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted immunotherapies for cancer and other difficult-to-treat diseases. Headquartered in Hampton, New Jersey, the company advances a pipeline of antibody-based therapeutics designed to engage the immune system. Key programs include barzolvolimab for chronic urticaria and mast cell-driven diseases, and CDX-0159 for inflammatory conditions. Celldex leverages its expertise in immunology to create novel treatments addressing significant unmet medical needs.